33676-00-5 Usage
Description
Hypophyllanthin, derived from the plant P. amarus, is an active principle with potential applications in the treatment of hepatotoxicity. It has been shown to reversibly inhibit P-glycoprotein (MDR1) function in Caco-2 cells without affecting MDR2 activity. HYPOPHYLLANTHIN is a polyphenolic antioxidant that can modulate various cellular processes.
Uses
Used in Pharmaceutical Research:
Hypophyllanthin is used as a research compound for studying the modulation of NSAID-induced, ER stress-mediated apoptosis in Caco-2 cells by different polyphenolic antioxidants. This application helps in understanding the potential therapeutic effects of hypophyllanthin in treating hepatotoxicity and other related conditions.
Used in Drug Delivery Systems:
Although not explicitly mentioned in the provided materials, hypophyllanthin's potential application in drug delivery systems can be inferred due to its antioxidant properties and ability to modulate cellular processes. It could be used as a component in the development of novel drug delivery systems to enhance the bioavailability and therapeutic outcomes of various medications.
Used in Anticancer Applications:
While the provided materials do not specifically mention hypophyllanthin's use in anticancer applications, its antioxidant properties and ability to modulate cellular processes suggest that it could potentially be investigated for its efficacy against cancer cells. Further research would be required to explore this application.
in vitro
previous study found that hypophyllanthin could inhibit p-gp function with comparable potencies, but could not affect mrp2 activity. when hypophyllanthin was washed out before addition of substrate, the inhibitory action against p-gp function was lost. these results indicated the reversibility of the inhibition. moreover, prolonged exposure of the caco-2 cells to hypophyllanthin up to 7 days had no effect on p-gp function [1].
in vivo
a previous study was conducted to evaluate the effect of carbofuran on estrous cycle and follicular growth in virgin wister rats as well as recovering from the damaged estrous cycle with treatment of hypophyllanthin. hypophyllanthin is non-steroidal plant molecule with estrogen-like activities, but with an estrogen-type activity. hypophyllanthin was capable of interacting with estrogen receptors, showing both agonist and antagonist methods of action. therefore, hypophyllanthin was found to be systemically transformed into enterolignan, which is known to be responsible for augmenting estrus cycle in rats [2].
references
[1] n. sukhaphirom, n. vardhanabhuti, h. chirdchupunseree, et al. phyllanthin and hypophyllanthin inhibit function of p-gp but not mrp2 in caco-2 cells. journal of pharmacy and pharmacology 65, 292-299 (2012). [2] aminul islam et al. estrogenic properties of phyllanthin and hypophyllanthin from phyllanthus amarus against carbofuran induced toxicity in female rats. pharmacologyonline 3: 1006-1016 (2008).
Check Digit Verification of cas no
The CAS Registry Mumber 33676-00-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,3,6,7 and 6 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 33676-00:
(7*3)+(6*3)+(5*6)+(4*7)+(3*6)+(2*0)+(1*0)=115
115 % 10 = 5
So 33676-00-5 is a valid CAS Registry Number.
InChI:InChI=1/C24H30O7/c1-25-11-16-8-15-10-20(29-5)23-24(31-13-30-23)22(15)21(17(16)12-26-2)14-6-7-18(27-3)19(9-14)28-4/h6-7,9-10,16-17,21H,8,11-13H2,1-5H3/t16-,17?,21+/m0/s1
33676-00-5Relevant articles and documents
Structure and Synthesis of the Aryltetralin Lignans Hypophyllanthin and Nirtetralin
Schneiders, Gail E.,Stevenson, Robert
, p. 999 - 1004 (2007/10/02)
Structures previously suggested for hypophyllanthin, the major aryltetralin lignan constituent of Phyllanthus niruri are shown to be incorrect.The structure r-1-(3,4-dimethoxyphenyl)-6-methoxy-t-2,c-3-bismethoxymethyl-7,8-methylenedioxy-1,2,3,4-tetrahydronaphthalene (5) now proposed is confirmed by an unambiguous synthesis.Synthesis of the congener, nirtetralin, is also described.
